Tesamorelin vs MK-677: Which Works Better?

The size of the global growth hormone market is projected to grow from an estimated $5.71 billion in 2025 to $10.18 billion by 2033, according to a recent report.

Both Tesamorelin and MK-677 fall in the growth hormone secretagogues (GHSs) category. These are the peptides that enable the regulation of the growth hormone (GH). While all GHSs elevate systemic GH level and its downstream effector, insulin-like growth factor 1 (IGF-1), they work differently. In fact, their dosing and administration protocols are significantly different. 

Tesamorelin: GHRH Analog

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). GHRH is a naturally occurring hormone that acts directly on the pituitary gland. It causes the release of GH. Tesamorelin stimulates the natural GH-production process with high specificity.

Mechanism 

Tesamorelin directly binds to GHRH receptors on the cells of the pituitary gland. This regulates the pulsatile release of GH. In short, it closely mimics the body’s natural physiological patterns. 

It is FDA-approved for a specific therapeutic indication: the reduction of deep belly fat in patients with HIV-associated lipodystrophy.

Benefits

Tesamorelin’s action is very precise. This specificity makes it suitable for targeted fat reduction and physiological GH Release. 

image 1

It is an FDA-approved prescription drug. This means that Tesamorelin can be trusted for safety and efficacy, which makes patients more comfortable in using it. Pharmacists can source premium peptides from Reverse Peptides for research on hormone regulation treatment.

Precautions

Tesamorelin therapy is done with daily subcutaneous injection. This can be a little uncomfortable for some users. This may also lead to reactions, such as redness, pain, or itching at the site. 

MK-677 (Ibutamoren): Oral Ghrelin Mimic

MK-677 is commonly known as Ibutamoren. It is a potent, non-peptide, orally active GH secretagogue. It functions as a ghrelin receptor (GHS-R1a).

Continue reading

Leave a Reply

Your email address will not be published. Required fields are marked *